Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.86
SNSS's Cash to Debt is ranked higher than
64% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SNSS: 3.86 )
SNSS' s 10-Year Cash to Debt Range
Min: 2.18   Max: No Debt
Current: 3.86

Equity to Asset 0.08
SNSS's Equity to Asset is ranked higher than
52% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SNSS: 0.08 )
SNSS' s 10-Year Equity to Asset Range
Min: -3.31   Max: 0.89
Current: 0.08

-3.31
0.89
F-Score: 3
Z-Score: -16.78
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -607.60
SNSS's Operating margin (%) is ranked higher than
59% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. SNSS: -607.60 )
SNSS' s 10-Year Operating margin (%) Range
Min: -64863.64   Max: -169.03
Current: -607.6

-64863.64
-169.03
Net-margin (%) -715.63
SNSS's Net-margin (%) is ranked higher than
58% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. SNSS: -715.63 )
SNSS' s 10-Year Net-margin (%) Range
Min: -74506.06   Max: -166.44
Current: -715.63

-74506.06
-166.44
ROE (%) -734.52
SNSS's ROE (%) is ranked lower than
52% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. SNSS: -734.52 )
SNSS' s 10-Year ROE (%) Range
Min: -1198.61   Max: -57.33
Current: -734.52

-1198.61
-57.33
ROA (%) -92.30
SNSS's ROA (%) is ranked higher than
54% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SNSS: -92.30 )
SNSS' s 10-Year ROA (%) Range
Min: -448.13   Max: -39.99
Current: -92.3

-448.13
-39.99
ROC (Joel Greenblatt) (%) -115868.72
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. SNSS: -115868.72 )
SNSS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -96281.82   Max: -460.2
Current: -115868.72

-96281.82
-460.2
EBITDA Growth (%) -14.60
SNSS's EBITDA Growth (%) is ranked higher than
69% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. SNSS: -14.60 )
SNSS' s 10-Year EBITDA Growth (%) Range
Min: -59.1   Max: -14.6
Current: -14.6

-59.1
-14.6
EPS Growth (%) -12.60
SNSS's EPS Growth (%) is ranked higher than
72% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SNSS: -12.60 )
SNSS' s 10-Year EPS Growth (%) Range
Min: -60.4   Max: 20.5
Current: -12.6

-60.4
20.5
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SNSS Guru Trades in Q4 2013

Jean-Marie Eveillard 239,956 sh (+19.98%)
» More
Q1 2014

SNSS Guru Trades in Q1 2014

Jim Simons 23,214 sh (New)
Steven Cohen 502,900 sh (New)
Jean-Marie Eveillard 219,557 sh (-8.5%)
» More
Q2 2014

SNSS Guru Trades in Q2 2014

Steven Cohen 468,500 sh (unchged)
Jim Simons 22,886 sh (-1.41%)
Jean-Marie Eveillard 200,000 sh (-8.91%)
» More
Q3 2014

SNSS Guru Trades in Q3 2014

Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-09-30 Sold Out $5.553 - $8.23 $ 2.25-67%0
Jean-Marie Eveillard 2013-09-30 New Buy$4.55 - $6.05 $ 2.25-56%200000
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$4 - $6.49 $ 2.25-57%0
Jean-Marie Eveillard 2012-09-30 Reduce -30.24%$2.95 - $5.76 $ 2.25-37%350000
Jean-Marie Eveillard 2012-06-30 New Buy0.01%$2.51 - $3.18 $ 2.25-19%501727
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 39.00
SNSS's P/B is ranked higher than
58% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. SNSS: 39.00 )
SNSS' s 10-Year P/B Range
Min: 1.01   Max: 297.5
Current: 39

1.01
297.5
P/S 19.50
SNSS's P/S is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. SNSS: 19.50 )
SNSS' s 10-Year P/S Range
Min: 0.95   Max: 157.25
Current: 19.5

0.95
157.25
EV-to-EBIT -2.69
SNSS's EV-to-EBIT is ranked higher than
55% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SNSS: -2.69 )
SNSS' s 10-Year EV-to-EBIT Range
Min: -11.7   Max: 3
Current: -2.69

-11.7
3
Current Ratio 1.23
SNSS's Current Ratio is ranked higher than
52% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SNSS: 1.23 )
SNSS' s 10-Year Current Ratio Range
Min: 0.71   Max: 12.17
Current: 1.23

0.71
12.17
Quick Ratio 1.23
SNSS's Quick Ratio is ranked higher than
55% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SNSS: 1.23 )
SNSS' s 10-Year Quick Ratio Range
Min: 0.71   Max: 12.17
Current: 1.23

0.71
12.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 58.50
SNSS's Price/Net Cash is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. SNSS: 58.50 )
SNSS' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 187
Current: 58.5

1.68
187
Price/Net Current Asset Value 58.50
SNSS's Price/Net Current Asset Value is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. SNSS: 58.50 )
SNSS' s 10-Year Price/Net Current Asset Value Range
Min: 1.68   Max: 187
Current: 58.5

1.68
187
Price/Tangible Book 39.00
SNSS's Price/Tangible Book is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. SNSS: 39.00 )
SNSS' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 273.5
Current: 39

1.6
273.5
Price/Median PS Value 2.11
SNSS's Price/Median PS Value is ranked higher than
76% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. SNSS: 2.11 )
SNSS' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 15.22
Current: 2.11

0.11
15.22
Earnings Yield (Greenblatt) -37.20
SNSS's Earnings Yield (Greenblatt) is ranked higher than
51% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. SNSS: -37.20 )
SNSS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 32.8   Max: 16670.9
Current: -37.2

32.8
16670.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany
Sunesis Pharmaceuticals, Inc., was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is a first-in-class anti-cancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. It has built an experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer. In December 2010, the Company commenced enrollment of a Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, a widely used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine. The Company owns development and commercialization rights to vosaroxin. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
comment on SNSS Mar 02 2013 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
cooldecency99 note on SNSS May 01 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
Sunesis Reports Financial Results for the Second Quarter 2009 Jul 29 2009 

More From Other Websites
Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology Nov 24 2014
Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology Nov 24 2014
Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica Nov 19 2014
Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica Nov 19 2014
SUNESIS PHARMACEUTICALS INC Financials Nov 18 2014
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% Nov 18 2014
Is This the Sunesis Resurrection? Nov 17 2014
Sunesis Pharmaceuticals Bounces On Results Announcement Nov 17 2014
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of Blood Cancer Treatment Data Nov 17 2014
Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual... Nov 17 2014
Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual... Nov 17 2014
10-Q for Sunesis Pharmaceuticals, Inc. Nov 12 2014
Sunesis Pharmaceuticals Inc Earnings Call scheduled for 10:30 am ET today Nov 10 2014
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights Nov 10 2014
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights Nov 10 2014
Sunesis to Present at Upcoming Investor Conferences Nov 05 2014
Sunesis to Present at Upcoming Investor Conferences Nov 05 2014
Sunesis to Host Conference Call on November 10th to Discuss Third Quarter 2014 Financial Results and... Nov 03 2014
Sunesis to Host Conference Call on November 10th to Discuss Third Quarter 2014 Financial Results and... Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK